Navigation Links
drugstore.com inc. Reports Record Gross Margins and Bottom Line Results for the Third Quarter of 2007
Date:10/22/2007

- Third Quarter Revenues Increase Year-over-Year to $107.3 Million and Net

Loss Decreases to $0.02 per Share - Company Expects to More Than Double Adjusted EBITDA in Fourth Quarter of

2007

BELLEVUE, Wash., Oct. 22 /PRNewswire-FirstCall/ -- drugstore.com, inc. (Nasdaq: DSCM), a leading online provider of health, beauty, vision, and pharmacy products, today announced its financial results for the third quarter ended September 30, 2007. The company reported quarterly net sales of $107.3 million and a net loss of $2.4 million, or $0.02 per share. The company achieved record performance across a number of key financial metrics: gross margins reached 23.2%, adjusted EBITDA was approximately $2.1 million and operating cash flow was $4.4 million. Adjusted EBITDA is a non-GAAP financial measure defined as earnings before interest, taxes, depreciation, and amortization of intangible assets and non-cash marketing expense, adjusted to exclude the impact of stock-based compensation expense.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070813/AQM043LOGO)

"In the seasonally challenging third quarter, we continued to grow our OTC business, reported strong gross margin improvement and record adjusted EBITDA," said Dawn Lepore, chief executive officer and chairman of the board of drugstore.com, inc. "OTC revenues increased by 20% year-over-year with a number of our key growth initiatives rolling out later in the quarter. Gross margins increased 170 basis points year-over-year leading to record adjusted EBITDA of $2.1 million, an improvement of over 57% from the same period in
'/>"/>

SOURCE drugstore.com, inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine news :

1. Autopsy reports could be valuable and informative
2. China reports declining number of SARS Cases
3. Russia Reports First SARS Case
4. Research reports that c-section deliveries are rising
5. Jharkhand reports 13,000 Malaria cases
6. Uganda Reports Failure To Contain Sleeping Sickness
7. WHO reports 36 million deaths world wide due to chronic diseases
8. Reports of Hantavirus infection in India raise concerns
9. Controversy Surrounding The HIV Positive Reports Of One-Year Girl In Kerala
10. China Reports Yet Another Bird Flu Case
11. China reports seventh bird flu victim
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2008)...tients treated with radiation prior to surgery for...ncer recurrence and better overall survival rates,...eport examined a treatment called neoadjuvant ther...t the spread of cancer, before surgery to remove t...rapy and/or radiation. , Neoadjuvant therapy sh...
(Date:12/2/2008)...2008 - Elsevier announced today the publication of...the theme of "Second trimester abortion: women,s h...on raises complex issues regarding methods, values...ery and the sometimes complicated reality of women...ve Health Matters grew out of a conference on sec...
(Date:12/2/2008)... probably higher with aprotinin, a drug commonly u...cardiac surgery, compared with lysine analogues, a...pdf/cmaj.081109 to be published in the January 20...anada expert advisory panel will meet to decide on...in advance of the meeting. , The study, a syste...
(Date:12/2/2008)... published in the December 1, 2008, issue of Clin...ssociation for Cancer Research, show lapatinib ben...e women with HER2-negative breast cancer or those ...it. In addition, a misclassification of metastatic...revents some people from receiving optimal therapy...
Breaking Medicine News(10 mins):Health News:Elsevier announces the 2008 supplement of Reproductive Health Matters 2Health News:HER2 levels may aid in treatment selection for metastatic breast cancer 2
...ing weight by dietary changes and increased physic...condition where blood glucose// levels are higher ...ese are the results of a new study that was publis...Care, of women who participated in the Diabetes Pr...
...e being hit the most by obesity-related disorders....ne by doctors that fails to// detect these problem...ight divided by height- is used in the standard me...ing to the experts, East and South Asians were aff...
...n Canada ahead of HIV/AIDS, diabetes and car accid...inal communities. With World// Suicide Prevention ... from the Canadian Institutes of Health Research (...lenges posed by suicide, its causes and possible p...
...er a period of 30 years and has infected many peop...Recently, 3 people in Delhi// have tested positive...rs who transmit chikungunya fever to human. The N...able Diseases (NICD) tested 6 blood samples of whi...
Other Medicine News:Health News:Bladder Control following Weight loss in women with Prediabetes 2Health News:Bladder Control following Weight loss in women with Prediabetes 3Health News:Getting Serious About Suicide Prevention 2
(Date:12/2/2008)...LA, Calif., Dec. 2 TorreyPines The...positive results from a 26 patient Phase II trial ...r xerostomia, or dry mouth, in patients with Sjogr... a statistically significant increase in salivary ...oses: 10 mg, 15 mg, and 20 mg. These doses were sa...
(Date:12/2/2008)..., Ill., Dec. 2 Horizon Therapeutic...ny, today announced that two pivotal,Phase 3 tria...didate, HZT-501,met all primary endpoints. HZT-5...roduct containing ibuprofen and famotidine, demons...he incidence of non-steroidal,anti-inflammatory d...
(Date:12/2/2008)...DA, Md., Dec. 2 Micromet...any developing novel, proprietary antibodies for t...e diseases, today announced that it has entered in...ancing Facility (CEFF) with Kingsbridge Capital Li...s of the agreement, Kingsbridge has committed to p...
(Date:12/1/2008)...O, Dec. 2 New research ...t-slice computed tomography (CT) scanner in an eme...of stroke victims who receive a potentially life-s...t North Shore Medical Center (NSMC)-Salem Hospital...nnual meeting of the Radiological Society of North...
Breaking Medicine Technology:TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia 2TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia 3TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia 4TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia 5Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 2Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 3Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 4Micromet Expands Committed Equity Financing Facility to $75 Million 2Micromet Expands Committed Equity Financing Facility to $75 Million 3Micromet Expands Committed Equity Financing Facility to $75 Million 4Micromet Expands Committed Equity Financing Facility to $75 Million 5Micromet Expands Committed Equity Financing Facility to $75 Million 6Portable CT Increases Chance of Stroke Survival and Recovery 2Portable CT Increases Chance of Stroke Survival and Recovery 3OneTouch 28R 29 Ping 28TM 29 Glucose Management System Cleared by FDA 23109 1OneTouch 28R 29 Ping 28TM 29 Glucose Management System Cleared by FDA 23109 2OneTouch 28R 29 Ping 28TM 29 Glucose Management System Cleared by FDA 23109 3New technique produces genetically identical stem cells 6347 1New technique produces genetically identical stem cells 6347 2Sign Language Associates and Visual Language Interpreting Combine With GoAmerica to Form Nations Premier Sign Language Interpreting Services Company 23105 1Sign Language Associates and Visual Language Interpreting Combine With GoAmerica to Form Nations Premier Sign Language Interpreting Services Company 23105 2Sign Language Associates and Visual Language Interpreting Combine With GoAmerica to Form Nations Premier Sign Language Interpreting Services Company 23105 3Sign Language Associates and Visual Language Interpreting Combine With GoAmerica to Form Nations Premier Sign Language Interpreting Services Company 23105 4Sign Language Associates and Visual Language Interpreting Combine With GoAmerica to Form Nations Premier Sign Language Interpreting Services Company 23105 5Novartis Pharmaceuticals Corporation to Appeal Judgment in Alabama Pricing Case 23101 1Novartis Pharmaceuticals Corporation to Appeal Judgment in Alabama Pricing Case 23101 2Novartis Pharmaceuticals Corporation to Appeal Judgment in Alabama Pricing Case 23101 3
...ta to be Presented April 15th at EASL Conference i...pril 11, 2007,/PRNewswire-FirstCall/ - MIGENIX Inc...ious diseases, has received new top-line results,c...s (November 6,2006) indicating evidence of clinic...study using the oral alpha-glucosidase,inhibitor, ...
...MBRIDGE, Mass.--(BUSINESS WIRE)--Apr 11, 2007 - Gl...d biopharmaceutical,company, announced today that ...omidepsin will be presented at the 2007,Annual Mee...h,taking place in Los Angeles, CA April 14-18, 200...preclinical research,performed by multiple academi...
Other Medicine Technology:New Clinical Study Results Indicate Higher Early Virologic Response,with Celgosivir Combination Therapy in HCV Non-Responders 2New Clinical Study Results Indicate Higher Early Virologic Response,with Celgosivir Combination Therapy in HCV Non-Responders 3New Clinical Study Results Indicate Higher Early Virologic Response,with Celgosivir Combination Therapy in HCV Non-Responders 4New Clinical Study Results Indicate Higher Early Virologic Response,with Celgosivir Combination Therapy in HCV Non-Responders 5New Clinical Study Results Indicate Higher Early Virologic Response,with Celgosivir Combination Therapy in HCV Non-Responders 6New Clinical Study Results Indicate Higher Early Virologic Response,with Celgosivir Combination Therapy in HCV Non-Responders 7New Clinical Study Results Indicate Higher Early Virologic Response,with Celgosivir Combination Therapy in HCV Non-Responders 8Gloucester Pharmaceuticals Announces Multiple Presentations of,Preclinical Romidepsin Data at American Association of Cancer,Research Annual Meeting 2Gloucester Pharmaceuticals Announces Multiple Presentations of,Preclinical Romidepsin Data at American Association of Cancer,Research Annual Meeting 3
VACUETTE paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients.
BD Vacutainer® Plus Plastic Serum Tubes have spray-coated silica and are used for serum determinations in chemistry, serology, and immunohematology.
Inquire
The inner wall of the tube is coated with spray-dried lithium, ammonium or sodium heparin. These additives are anti-coagulants, which activate anti-thrombins, thus blocking the coagulation cascade of
Medicine Products: